Intercept strikes market sweet spot with $75m IPO
This article was originally published in Scrip
Executive Summary
Intercept Pharmaceuticals seems to have found the mood of the stock market with its $75 million initial public offering of 5 million shares priced at $15 per share on 11 October. Unlike many recent IPOs, New York-based Intercept did not have to reduce the size or price of its offering in order to encourage investors to buy in.